A Placebo Straw Man

I acknowledge this setup is a bit of a straw man, but it’s still a justification I hear from time to time so it’s worth examining.

The argument goes that we should be performing certain interventions, such as providing oxygen for pain control, despite them having no evidence basis or even a plausible mechanism because they harness the placebo effect.

“Here’s some oxygen; it will make you feel better.”
Click image for source.

The placebo effect is a real phenomenon and it can (and, some argue, sometimes should) be harnessed to improve a patient’s perception of their outcome. In select cases it can even affect objective physiological measurements. The merits of if and when we should be providing placebos have been debated for years.

There is one common circumstance when we certainly should NOT be administering placebos, however, and that is when there is an intervention or treatment available that has been proven superior. That is the case in my “oxygen for pain control” straw man.

Sure, it would be nice if prehospital care could be simplified by managing the patient with an isolated humerus fracture at the BLS level—especially on days when the paramedic is seeing three ALS calls for every BLS the Basic takes—but this is not the time to try and even the case load.

There are plenty of pharmacological agents available that have been proven superior to placebo for pain control, so when the former options are available, it is decidedly wrong to try and scrape by on latter. Maybe one could make a case for giving oxygen as a stop-gap in a truly rural setting where BLS is the only level of transport available, but the point of this discussion isn’t to delve into these specifics and what-ifs.

It is to drive home the point that administering oxygen for pain control is not just ridiculous, it is unethical when alternatives that have been proven superior to placebo are available.

Can you think of any other interventions we provide in prehospital and emergency medicine that also fit this bill?

Placebo means never having to say you’re sorry

 

Often in clinical research it seems like the placebo effect was put on earth solely to cause us headaches. Imagine how simple things would be without it. Controls? Who needs ’em? Just grab a bunch of random dudes with the disease and check back in a month to establish your baseline. Easy peasy.

But here’s another way of looking at it. One of the central tenets of modern EBM is that only treatment benefits above and beyond the effect of placebo (sometimes called “specific” effects) are “real” benefits worth pursuing. In other words, if your drug cured 50% of patients, but a placebo also cured 50%, then your drug had a net effect of zero and did nothing.

This is because we’d like to have medicines that work via the mechanisms we designed them to have, or at least in somewhat predictable and understandable ways. If a sugar pill cures a bunch of people, that’s very nice, but it’s not really medicine, is it? It’s some kind of mind-over-matter trollop that we refuse to accept in our wards.

There are some interesting ethical questions here. For instance, if you’re the one suffering from a painful, debilitating, or deadly disease, do you care if you’re cured by a sugar pill or an exhaustively-developed organic compound? If you feel better, can I really pop from behind a bush and say, “Gotcha! That was the fake stuff! You don’t feel better at all!” And if the placebo benefit hinges on the patient not knowing the truth, would it be ethical to start passing around fake (but effective) drugs?

The current attitude is no. This business leaves a sour taste in our collective mouths, perhaps because medicine spent so many centuries practicing exactly this sort of handwaving mumbo-jumbo. We consider ourselves scientists, and scientists treat using physiological mechanisms, not wishful thinking. Perhaps more importantly, we have an ethical problem with lying to our patients, which seems like a necessary part of intentionally wielding placebos.

But it behooves us to remember that despite all this, the placebo effect can indeed be dramatic and beneficial. That’s the whole reason we try to control for it in trials — because otherwise, every random treatment would look pretty impressive, even if there’s nothing under the hood. No benefit over placebo is often still a big benefit to the patient.

What’s my point? My point is this: in the ivory towers of EBM, we spend a lot of time stroking our beards and worrying that we’re subjecting our patients to drugs, surgeries, and interventions that are not evidence-based. Perhaps there’s even evidence that they’re ineffective, or sometimes even harmful. Until we can banish all such snake oil from our practice, we believe that we’re wasting our patients’ time and money at best and harming them at worst.

But the fact is, this probably isn’t so. Because even our worst snake oil is still convincing, and it probably still carries with it real placebo value. (In fact, this is often why anecdotal reports of treatment success abound even when the controlled trials say “nope.”) When we say that Drug X has no benefit, we mean that it added nothing compared against a placebo — but in clinical practice, we’re not comparing it against anything, we’re just giving it to sick people. In other words, it is the placebo, with all the associated power.

So even without any “specific” effect, odds are that it has some value anyway. It’s not zero, and in fact, the benefit may even outweigh some specific harms.

And so, ladies and gentlemen, we should keep fighting the good fight to rid ourselves of myth and hokum. But in the meanwhile, we shouldn’t lose too much sleep that we’re hurting anyone, because we’d have to hurt them quite a bit to outweigh that sugary placebo goodness.

 

Does NEXUS work in the elderly?

There aren't a lot of studies specifically examining whether the NEXUS criteria are reliable (e.g. don't miss important C-spine injuries) in the elderly. Most of the big studies that derived and validated the NEXUS rule enrolled patients of all … [Continue reading]

Epi Timing in Cardiac Arrest (Part 2)

Click to enlarge.

In our last post we examined the effect of the chosen resuscitation end-time on the overall duration of the resuscitation and how that affected the calculated mean time-interval between epinephrine doses. It's worth reviewing quickly before we resume … [Continue reading]

Epi Timing in Cardiac Arrest (Part 1)

5-6min Epi Interval

There’s a new study by Warren et al. out in the most resent issue of Resuscitation that examines the use of epinephrine during in-hospital cardiac arrest. It also purports to show a possible benefit to non-standard dosing regimens. Your pupils … [Continue reading]

No opinion less interesting than an expert opinion

Justice

The Greek philosopher Diogenes used to wander around in broad daylight with a lit lantern. Whenever anybody asked, he'd tell them he was looking for an honest man. Good luck with that. Who do we get to write clinical guidelines? Or even to … [Continue reading]

Graphtistical Tomfoolery

Correlation versus causation

There's a great Facebook post making the rounds which is worth the read for anyone amused by statistical smoke-and-mirrors. Hopefully it's not news to anybody that correlation isn't the same thing as causation. But it still seems to surprise some … [Continue reading]

DRL Update

8 new papers have been added to the Digital Research Library. Three are in the Cardiac Arrest shelf, including some important recent stuff on steroids and epi; the other five are in the Miscellaneous section, ranging through Trauma, Hematology, … [Continue reading]

Outcomes (and why you don’t get to supersize them)

Bullseye

Many people have trouble understanding outcomes. Obviously, the outcome is whatever a study is measuring -- the results. But what's the difference between primary and secondary outcomes? Why is it important to specify them before the study is … [Continue reading]

EMTLife Journal Club: The utility of gestures in patients with chest discomfort

New Journal Club at EMT Life. Does the gesture used by a patient to indicate his chest pain or discomfort have predictive value of an ischemic etiology? In other words, can you say "He pointed with his whole fist -- it must be an MI?" Or is that … [Continue reading]